$TCRT
Alaunos Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023063354 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $1.000K $0.00
YoY Change -90.91% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.428M $3.580M
YoY Change -16.99% 9.08%
% of Gross Profit
Research & Development $933.0K $3.656M
YoY Change -83.36% -53.68%
% of Gross Profit
Depreciation & Amortization $245.0K $670.0K
YoY Change -64.7% -3.04%
% of Gross Profit
Operating Expenses $3.361M $8.664M
YoY Change -60.61% -22.47%
Operating Profit -$8.664M
YoY Change 4.84%
Interest Expense $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $106.0K $188.0K
YoY Change -57.6% -132.03%
Pretax Income -$7.843M -$8.480M
YoY Change -14.37% -4.19%
Income Tax
% Of Pretax Income
Net Earnings -$7.843M -$8.476M
YoY Change -14.37% -4.24%
Net Earnings / Revenue -784300.0%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.49 -$0.04
COMMON SHARES
Basic Shares Outstanding 240.6M 240.6M
Diluted Shares Outstanding 240.0M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.062M $11.90M
YoY Change -84.48% -68.52%
Cash & Equivalents $6.062M $11.94M
Short-Term Investments
Other Short-Term Assets $2.198M $900.0K
YoY Change -85.09% -93.91%
Inventory
Prepaid Expenses
Receivables $1.000K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $8.261M $12.87M
YoY Change -84.64% -76.81%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K $5.532M
YoY Change -99.98% -38.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $2.000K $6.571M
YoY Change -99.98% -44.5%
TOTAL ASSETS
Total Short-Term Assets $8.261M $12.87M
Total Long-Term Assets $2.000K $6.571M
Total Assets $8.263M $19.44M
YoY Change -87.28% -71.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $616.0K $1.298M
YoY Change -55.65% -34.58%
Accrued Expenses $1.340M $3.071M
YoY Change -75.43% -59.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $1.956M $4.676M
YoY Change -91.91% -85.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.956M $4.676M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.956M $5.540M
YoY Change -92.59% -84.28%
SHAREHOLDERS EQUITY
Retained Earnings -$915.8M -$907.9M
YoY Change 4.0% 4.18%
Common Stock $922.1M $921.8M
YoY Change 0.31% 2.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.307M $13.90M
YoY Change
Total Liabilities & Shareholders Equity $8.263M $19.44M
YoY Change -87.28% -71.13%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$7.843M -$8.476M
YoY Change -14.37% -4.24%
Depreciation, Depletion And Amortization $245.0K $670.0K
YoY Change -64.7% -3.04%
Cash From Operating Activities -$7.382M -$6.380M
YoY Change 3.53% 3.82%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K $0.00
YoY Change -102.59% -100.0%
Acquisitions
YoY Change
Other Investing Activities $1.503M $0.00
YoY Change 6434.78%
Cash From Investing Activities $1.506M $0.00
YoY Change -1719.35% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.000K 0.000
YoY Change -99.98% -100.0%
NET CHANGE
Cash From Operating Activities -7.382M -6.380M
Cash From Investing Activities 1.506M 0.000
Cash From Financing Activities 2.000K 0.000
Net Change In Cash -5.874M -6.380M
YoY Change -569.54% -22.82%
FREE CASH FLOW
Cash From Operating Activities -$7.382M -$6.380M
Capital Expenditures -$3.000K $0.00
Free Cash Flow -$7.379M -$6.380M
YoY Change 1.84% 4.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33038
dei Entity Registrant Name
EntityRegistrantName
Alaunos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
dei Entity Address Address Line1
EntityAddressAddressLine1
8030 El Rio Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
dei City Area Code
CityAreaCode
346
dei Local Phone Number
LocalPhoneNumber
355-4099
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TCRT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
240627055
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11944000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39058000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
13938000
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
0
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
4000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
925000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
799000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
12869000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
53799000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5532000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8460000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1039000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2136000
CY2023Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
0
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000
CY2023Q3 us-gaap Assets
Assets
19440000
CY2022Q4 us-gaap Assets
Assets
64937000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1298000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1389000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
16765000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3071000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5454000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
307000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
558000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4676000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24166000
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
864000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2188000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2023Q3 us-gaap Liabilities
Liabilities
5540000
CY2022Q4 us-gaap Liabilities
Liabilities
26382000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
520000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
240627055
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
240627055
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
420000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
240410761
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
240410761
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
241000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
240000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
921583000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
918942000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-907924000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-880627000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13900000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38555000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19440000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64937000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2911000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2911000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3656000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7893000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15346000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19411000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3578000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3282000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9791000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10217000
CY2023Q3 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
CY2022Q3 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
245000
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
133000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
419000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
419000
us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q3 tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
1011000
CY2022Q3 tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
0
tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
1011000
tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
0
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8664000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11175000
us-gaap Operating Expenses
OperatingExpenses
26322000
us-gaap Operating Expenses
OperatingExpenses
29495000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8664000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8264000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26318000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26584000
CY2023Q3 us-gaap Interest Expense
InterestExpense
0
CY2022Q3 us-gaap Interest Expense
InterestExpense
841000
us-gaap Interest Expense
InterestExpense
1921000
us-gaap Interest Expense
InterestExpense
2266000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
188000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
254000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
942000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
279000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
188000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-587000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-979000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1987000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8476000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8851000
us-gaap Net Income Loss
NetIncomeLoss
-27297000
us-gaap Net Income Loss
NetIncomeLoss
-28571000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
240046026
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
240046026
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
215098995
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
215098995
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
239842327
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
239842327
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
215015377
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
215015377
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
21650000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
726000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8476000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13900000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38555000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2550000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
92000
us-gaap Net Income Loss
NetIncomeLoss
-27297000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13900000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40180000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
808000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
45000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8851000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
32113000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2651000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
45000
us-gaap Net Income Loss
NetIncomeLoss
-28571000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
32113000
us-gaap Net Income Loss
NetIncomeLoss
-27297000
us-gaap Net Income Loss
NetIncomeLoss
-28571000
us-gaap Depreciation
Depreciation
2074000
us-gaap Depreciation
Depreciation
2065000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1011000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1339000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
634000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
2550000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
2651000
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-1332000
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-2306000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
245000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
133000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1800000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
126000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-817000
tcrt Increase Decrease In Operating Deposits
IncreaseDecreaseInOperatingDeposits
42000
tcrt Increase Decrease In Operating Deposits
IncreaseDecreaseInOperatingDeposits
0
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-500000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-131000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-92000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
616000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2258000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1525000
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1575000
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2371000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-28000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
28000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22757000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22102000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
197000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
100000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
40000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-157000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
45000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
18105000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2083000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
125000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-18138000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2107000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41052000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24309000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52996000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76054000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11944000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51745000
us-gaap Interest Paid Net
InterestPaidNet
2063000
us-gaap Interest Paid Net
InterestPaidNet
1603000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
348000
CY2023Q3 tcrt Intended Percentage Of Resduction In Workforce
IntendedPercentageOfResductionInWorkforce
0.80
CY2023Q3 tcrt Strategic Advisor Name
StrategicAdvisorName
Cantor
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11900000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-907900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our accrued expenses represent estimates of activity and costs incurred with vendors and counterparties. During the three and nine months ended September 30, 2023, the Company revised estimated accrued expenses related to de-prioritized clinical programs based on new information received from vendors. As a result, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million credit has been recorded in research and development expense within the condensed statement of operations for the three months ended September 30, 2023, and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million credit has been recorded for the nine months ended September 30, 2023.</span></p>
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
0
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
16765000
CY2021Q3 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.045
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0
us-gaap Interest Expense Debt
InterestExpenseDebt
1900000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
800000
us-gaap Interest Expense Debt
InterestExpenseDebt
2300000
CY2023Q3 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1000000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10408622
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.84
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35776871
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34485557
CY2022Q2 tcrt Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
100000
tcrt Lease Termination Date
LeaseTerminationDate
2023-04-19
CY2023Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
a term expiring on June 30, 2025 with an option to extend through July 31, 2026
CY2023Q2 tcrt Sublease Term Commenced End Date Amendment
SubleaseTermCommencedEndDateAmendment
2026-07-31
tcrt Termination Costs
TerminationCosts
200000
CY2023Q4 tcrt Operating Lease Area
OperatingLeaseArea
14037
CY2023Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2018Q4 tcrt Maximum Royalty Amount
MaximumRoyaltyAmount
100000000
CY2023Q3 us-gaap Royalty Expense
RoyaltyExpense
0
CY2022Q3 us-gaap Royalty Expense
RoyaltyExpense
0
us-gaap Royalty Expense
RoyaltyExpense
0
us-gaap Royalty Expense
RoyaltyExpense
0
CY2023Q1 us-gaap Loss Contingency Name Of Plaintiff
LossContingencyNameOfPlaintiff
KBI Biopharma
CY2023Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3200000
CY2023Q3 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
1000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3695167
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
726000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
808000
us-gaap Share Based Compensation
ShareBasedCompensation
2550000
us-gaap Share Based Compensation
ShareBasedCompensation
2651000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3695167
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.39
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1275000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
7150438
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.91
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0401
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0294
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0362
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0351
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0401
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0163
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0362
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9065
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8243
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8589
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8969
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9563
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7449
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8589
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1686760
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.35
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12417029
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M20D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6126738
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M21D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3891598
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.46
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y29D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
13451681
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000
CY2023Q3 tcrt Intended Percentage Of Resduction In Workforce
IntendedPercentageOfResductionInWorkforce
0.60
CY2023Q3 us-gaap Severance Costs1
SeveranceCosts1
400000
us-gaap Severance Costs1
SeveranceCosts1
400000

Files In Submission

Name View Source Status
0000950170-23-063354-index-headers.html Edgar Link pending
0000950170-23-063354-index.html Edgar Link pending
0000950170-23-063354.txt Edgar Link pending
0000950170-23-063354-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img160813313_0.jpg Edgar Link pending
img41163667_0.jpg Edgar Link pending
img42087188_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcrt-20230930.htm Edgar Link pending
tcrt-20230930.xsd Edgar Link pending
tcrt-ex10_1.htm Edgar Link pending
tcrt-ex10_2.htm Edgar Link pending
tcrt-ex31_1.htm Edgar Link pending
tcrt-ex32_1.htm Edgar Link pending
tcrt-20230930_cal.xml Edgar Link unprocessable
tcrt-20230930_pre.xml Edgar Link unprocessable
tcrt-20230930_lab.xml Edgar Link unprocessable
tcrt-20230930_def.xml Edgar Link unprocessable
tcrt-20230930_htm.xml Edgar Link completed